<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82236">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01816048</url>
  </required_header>
  <id_info>
    <org_study_id>CO12810</org_study_id>
    <nct_id>NCT01816048</nct_id>
  </id_info>
  <brief_title>NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis</brief_title>
  <official_title>A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether NaF PET/CT scans can be used to evaluate
      treatment response  in  bone metastases in subjects with prostate cancer treated with the
      investigational drug, TAK-700.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To measure changes in NaF PET/CT standardized uptake values (SUVmean and SUV max) from prior to dosing with Tak-700 to 4-8 weeks after starting treatment with TAK-700</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure prostate specific antigen (PSA) response rate in patients treated with TAK700, as measured by a decline in the PSA level from baseline to the month 3 assessment according to the Prostate Cancer Clinical Trials Working Group (PCWG2)</measure>
    <time_frame>baseline to month 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who experience adverse events while on treatment with TAK 700</measure>
    <time_frame>Approximately 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure change in PSA kinetics with TAK700 from baseline to off treatment</measure>
    <time_frame>baseline and off treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure changes in NaF PET/CT results in response to TAK700</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is an exploratory endpoint a we are planning to identify other new parameters during the PET/CT scanning that may be more predictive of response (such as SUV volume, or dynamic changes during the scanning period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare changes on NaF PET/CT after treatment with TAK700 with standard clinical outcomes including PSA doubling time, response evaluation criteria in solid tumors (RECIST), and radiographic progression free survival.</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To document the change in the number of circulating tumor cells using one or more methods -includes PSA Elispot, flow cytometry and the VeriFAST platform</measure>
    <time_frame>baseline, one month, 3 months and at off study visit</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To document change in the number of circulating tumor cells using the cell search system (Veridex, LLC) obtained prior to beginning treatment with TAK 700, after completing one cycle and after completing 3 cycles.</measure>
    <time_frame>baseline, one month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare PSA response rate and circulating tumor cell counts of subjects receiving TAK700 to NaF PET/CT imaging results</measure>
    <time_frame>Baseline, one month, 2 months, 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>TAK-700</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-700 will be administered at 300 mg orally (PO)twice daily (BID) continuously on 28-day treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-700</intervention_name>
    <description>TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles</description>
    <arm_group_label>TAK-700</arm_group_label>
    <other_name>orteronel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients 18 years or older

          -  Voluntary written consent

          -  Histologically proven adenocarcinoma of the prostate

          -  Evidence of radiographic bone metastases

          -  May have received prior chemotherapy for metastatic disease, but prior chemotherapy
             is not a requirement for eligibility

          -  Eastern Cooperative Oncology Group performance status 0-2

          -  Serum testosterone level is less than or equal to 50 ng/dL

          -  Has undergone orchiectomy or plan to continue receiving gonadotropin releasing
             hormone (GnRH) analogue therapy

          -  Adequate organ function as measured by screening laboratory values specified in the
             protocol

          -  Must agree to use appropriate contraceptives prior to study procedures, during
             duration of study participation and for 4 months after last dose of TAK 700

          -  Must be able to lie flat for greater than or equal to 30 minutes during PET/CT
             imaging

          -  Screening calculated ejection fraction of greater than or equal to 50% by multigated
             radionuclide angiography (MUGA) scan or Echocardiogram

        Exclusion Criteria:

          -  Received Strontium-89, Samarium-153, or other radioisotope within 3 months of
             registration

          -  history of allergic reactions attributed to compounds similar to sodium fluoride F-18
             (NaF)

          -  history of seizure disorder

          -  Known history of brain metastases

          -  Concurrent treatment with any herbal products within 7 days of study entry

          -  Received radiotherapy less than or equal to 4 weeks prior to registration

          -  Known hypersensitivity to TAK-700 or related compounds

          -  Prior therapy for treatment of metastatic castrate resistant prostate cancer with any
             androgen biosynthesis inhibitor or androgen signaling pathway inhibitor such as:
             enzalutamide (MDV-3100), abiraterone, ketoconazole, or aminoglutethimide

          -  Current bladder neck outlet obstruction

          -  Current spinal cord compression

          -  Current bilateral hydronephrosis

          -  History of adrenal insufficiency

          -  History of myocardial infarction, unstable symptomatic ischemic heart disease,
             ongoing arrhythmias (over grade 2), thromboembolic events, or any other cardiac
             condition within 6 months prior to first dose of study drug.

          -  Uncontrolled high blood pressure

          -  Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
             hepatitis C

          -  Major surgery less than or equal to 4 weeks before the first dose of study drug

          -  Serious infection less than or equal to 2 weeks before the first dose of study drug

          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with oral
             absorption or tolerance of TAK-700, including difficulty swallowing capsules
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justine Y Bruce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cancer Connect UW Carbone Cancer Center</last_name>
    <phone>1-800-622-8922</phone>
    <email>cancerconnect@uwcarbone.wisc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 11, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate, prostate cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
